Patient enrolment completed for fruquintinib’s Phase II study in non-small cell lung cancer

10-Mar-2015 - Hong Kong

Chi-Med nnounces that Hutchison MediPharma Limited (HMP) has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung cancer (NSCLC) patients in China.  The proof-of-concept study is investigating the efficacy and safety of fruquintinib, HMP’s investigational small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR).

This randomised, double-blind, placebo-controlled, multi-centre, POC Phase II study is targeted at treating non-squamous NSCLC patients who have failed second-line standard chemotherapy.  A total of 91 patients have now been randomised to receive fruquintinib plus best supportive care or placebo plus BSC at a 2:1 ratio. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety.  As a result of the rapid patient enrolment, data from this trial is expected in mid of 2015.

Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances